专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20040047876A1 Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins 审中-公开
标题翻译：用热休克/应激蛋白预防和治疗原发性和转移性肿瘤性疾病和传染病的组合物和方法
公开(公告)号：US20040047876A1
公开(公告)日：2004-03-11
申请号：US10640604
申请日：2003-08-12
申请人： Fordham University.
发明人： Pramod K. Srivastava
IPC分类号： A61K039/00
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/52 , A61K2039/525 , A61K2039/6043 , A61K2039/622 , G01N33/56977 , G01N33/574 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , Y10S435/81
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. nullAntigenic moleculenull as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and is derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8null cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.
摘要翻译：本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不络合的）或抗原性/免疫原性片段，并且是其衍生物。在优选的实施方案中，复合物是个体自体的。复合物的有效量对于包含hsp70，hsp90为50-1000微克，gp96为10-600微克的复合物为10-600微克。本发明还提供了一种在个体，优选人体内测量体内肿瘤排斥的方法，包括测量个体对肿瘤特异性的MHC I类限制性CD8 +细胞毒性T淋巴细胞的产生。还提供了纯化hsp70-肽复合物的方法。

12. 发明申请

WO1997010002A1 IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASE USING ANTIGEN-PRESENTING CELLS SENSITIZED WITH HEAT SHOCK PROTEIN-ANTIGEN COMPLEXES 审中-公开
标题翻译：使用抗高温蛋白抗原复合物的抗原细胞免疫癌和感染性疾病的免疫治疗
公开(公告)号：WO1997010002A1
公开(公告)日：1997-03-20
申请号：PCT/US1996014558
申请日：1996-09-11
申请人： FORDHAM UNIVERSITY
发明人： FORDHAM UNIVERSITY , SRIVASTAVA, Pramod, K.
IPC分类号： A61K39/385
CPC分类号： A61K39/0011 , A61K38/191 , A61K38/20 , A61K38/21 , A61K2039/5154 , A61K2039/6043 , A61K2039/622 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , A61K2300/00
摘要： The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon- alpha , interferon- alpha , interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.
摘要翻译：本发明涉及用于增强免疫应答和用于预防和治疗感染性疾病或原发性和转移性肿瘤性疾病的方法和组合物，其基于施用热休克蛋白非特异性的巨噬细胞和/或其他抗原呈递细胞（APC）共价结合肽复合物和/或抗原成分。 APC在体外在hsp-肽复合物和/或抗原成分存在下孵育。致敏细胞用或不用细胞因子包括但不限于干扰素-α，干扰素-α，白介素-2，白细胞介素-4，白细胞介素-6和肿瘤神经元因子治疗而被再灌注入患者。

13. 发明申请

US20030012793A1 Compositions and methods for promoting tissue repair using heat shock proteins 审中-公开
标题翻译：使用热休克蛋白促进组织修复的组合物和方法
公开(公告)号：US20030012793A1
公开(公告)日：2003-01-16
申请号：US10174786
申请日：2002-06-18
申请人： Fordham University
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： A61K039/00 , A61K038/17
CPC分类号： A61K38/1709 , A61K2300/00
摘要： The invention relates to methods and compositions for the promotion of tissue repair. Specifically, compositions comprising heat shock proteins, including gp96, hsp90, and hsp70, uncompleted or completed noncovalently with antigenic molecules, are disclosed. Therapeutic methods for administering the hsp-containing compositions are disclosed. The disclosed methods are useful for promoting repair of tissues that were disrupted by a variety of causes including trauma (e.g., surgery, injury or burns) or disease or disorder (e.g., atherosclerosis and multiple sclerosis).
摘要翻译：本发明涉及用于促进组织修复的方法和组合物。具体地，公开了包含热休克蛋白，包括gp96，hsp90和hsp70的组合物，其未完全或完全与抗原性分子非共价结合。公开了用于施用含hsp的组合物的治疗方法。所公开的方法可用于促进由包括创伤（例如手术，损伤或烧伤）或疾病或病症（例如动脉粥样硬化和多发性硬化））的多种原因破坏的组织的修复。

14. 发明申请

WO2001017554A1 METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GRAFT REJECTION USING HEAT SHOCK PROTEINS 审中-公开
标题翻译：治疗和预防使用热休克蛋白抑制剂的方法和组合物
公开(公告)号：WO2001017554A1
公开(公告)日：2001-03-15
申请号：PCT/US2000/024711
申请日：2000-09-08
申请人： FORDHAM UNIVERSITY , SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
发明人： SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
IPC分类号： A61K39/385
CPC分类号： A61K39/001 , A61K2039/6043 , A61K2039/622
摘要： Methods for treatment and prevention of graft rejection, e.g., in response to tissue or organ transplantation, are disclosed. The disclosed methods comprise administration of compositions of complexes of heat shock/stress protein (hsps) including, but not limited to, hsp70, hsp90, and gp96, either alone or in combination with each other, noncovalently bound to antigenic molecules, to suppress the immune response to the grafted tissue or organ. In addition, administration of compositions containing un-complexed stress proteins (i.e., free of antigenic molecules) to suppress the immune response to the grafted tissue or organ are also disclosed. The invention encompasses administration of heat shock proteins before, after, or both before and after transplantation or grafting. In addition, the invention encompasses administration of donor tissue sample prior to administration of heat shock protein and subsequent transplantation or grafting.
摘要翻译：公开了用于治疗和预防移植排斥反应的方法，例如响应于组织或器官移植。所公开的方法包括非共价结合抗原分子的单独或彼此组合的包括但不限于hsp70，hsp90和gp96的热休克/应激蛋白（hsps）复合物的组合物，以抑制对移植组织或器官的免疫应答。此外，还公开了含有非复合应激蛋白（即，不含抗原性分子）的组合物的给药以抑制对移植组织或器官的免疫应答。本发明包括在移植或移植之前，之后或之前施用热休克蛋白。此外，本发明包括在给予热休克蛋白之前施用供体组织样品，随后进行移植或移植。

15. 发明申请

WO1997010001A1 TREATMENT OR PREVENTION OF NEOPLASTIC AND INFECTIOUS DISEASES WITH HEAT SHOCK/STRESS PROTEINS 审中-公开
标题翻译：用热冲击/应激蛋白治疗或预防神经性和感染性疾病
公开(公告)号：WO1997010001A1
公开(公告)日：1997-03-20
申请号：PCT/US1996014557
申请日：1996-09-11
申请人： FORDHAM UNIVERSITY
发明人： FORDHAM UNIVERSITY , SRIVASTAVA, Pramod, K.
IPC分类号： A61K39/385
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/52 , A61K2039/525 , A61K2039/6043 , A61K2039/622 , G01N33/56977 , G01N33/574 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , Y10S435/81
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 100-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.
摘要翻译：本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即，hsps在体内不复合的肽或其抗原性/免疫原性片段及其衍生物）复合物对于个体是自体的，复合物的有效量对于包含hsp70，hsp90为50-1000微克，gp96为10-600微克的复合物为100-600微克，本发明还提供一种用于测量个体，优选人体内肿瘤排斥反应的方法，包括测量个体对肿瘤特异性的MHC I类限制性CD8 +细胞毒性T淋巴细胞的产生。还提供了纯化hsp70-肽复合物的方法。

16. 发明申请

US20140030628A1 PHOTOCATALYTIC FUEL CELL AND ELECTRODE THEREOF 审中-公开
标题翻译：光电燃料电池及其电极
公开(公告)号：US20140030628A1
公开(公告)日：2014-01-30
申请号：US13950424
申请日：2013-07-25
申请人： Fordham University
发明人： John J. McMahon
IPC分类号： H01M4/86 , H01L29/40
CPC分类号： H01M4/8657 , H01L29/401 , H01M4/9041 , H01M4/921 , H01M4/94 , H01M8/00 , H01M14/00 , H01M2004/8689 , Y02P70/56
摘要： The invention provides a novel fuel cell, the output voltage of which is pH dependent. The fuel cell comprises a membrane electrode assembly and a light source. In accordance with one embodiment, the membrane electrode assembly includes i) an electrolyte; ii) an anode operably coupled to the electrolyte; and iii) a cathode operably coupled to the electrolyte, wherein the cathode is made from an electrically conductive material and has an unroughened surface where an adsorbate material is applied. The adsorbate material used herein comprises a material having semiconductor properties, and the combination of the electrically conductive material and the adsorbate material is photosensitive and has catalytic properties. The invention also provides a novel electrode that can be used as a cathode in a fuel cell, a novel method for making the electrode, and a novel method of generating electricity using the fuel cell and/or electrode of the invention.
摘要翻译：本发明提供了一种新颖的燃料电池，其输出电压是pH依赖性的。燃料电池包括膜电极组件和光源。根据一个实施例，膜电极组件包括i）电解质; ii）可操作地耦合到电解质的阳极; 以及iii）可操作地耦合到所述电解质的阴极，其中所述阴极由导电材料制成并且具有未被增韧的表面，其中施加了被吸附材料。本文所用的被吸附材料包括具有半导体特性的材料，并且导电材料和被吸附材料的组合是光敏的并具有催化性质。本发明还提供了可用作燃料电池中的阴极的新型电极，制造电极的新方法，以及使用本发明的燃料电池和/或电极产生电力的新方法。

17. 发明申请

US20030012794A1 Kits comprising heat shock protein-antigenic molecule complexes 审中-公开
标题翻译：试剂盒包含热休克蛋白 - 抗原分子复合物
公开(公告)号：US20030012794A1
公开(公告)日：2003-01-16
申请号：US10212031
申请日：2002-08-02
申请人： Fordham University
发明人： Pramod K. Srivastava , Rajiv Y. Chandawarkar
IPC分类号： A61K039/00
CPC分类号： A61K39/0011 , A61K2039/6043 , A61K2039/622 , Y02A50/466
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. nullAntigenic moleculenull as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.
摘要翻译：本发明涉及引发免疫应答的方法和组合物以及预防和治疗原发性和转移性肿瘤性疾病和感染性疾病。本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组成。任选地，所述方法还包括施用用非共价结合于抗原分子的hsps复合物致敏的抗原呈递细胞。本文所用的“抗原分子”是指hsps与体内内源性相关的肽以及外源性抗原/免疫原（即hsps在体内不复合）或其抗原/免疫原性片段及其衍生物。在优选的实施方案中，复合物是个体自体的。在一个具体实施方案中，对于包含hsp70,5-449微克对于hsp90和对于gp96为0.1至9.0微克的复合物，复合物的有效量在0.1至9.0微克范围内。

18. 发明授权

US11879176B2 Metal oxide nanowires in supported nanoparticle catalysis 有权
公开(公告)号：US11879176B2
公开(公告)日：2024-01-23
申请号：US16739498
申请日：2020-01-10
申请人： Fordham University
发明人： Christopher Koenigsmann , Alexander Charles Santulli
IPC分类号： C25B11/04 , C25B1/00 , C25B11/081 , C25B11/057 , H01M4/92 , H01M4/90 , B82Y30/00
CPC分类号： C25B11/081 , C25B11/057 , H01M4/9075 , H01M4/925 , B82Y30/00
摘要： The present disclosure is concerned with metal oxide nanowires, and more specifically, to crystalline ruthenium oxide (RuO2) nanowires, sol-gel synthetic methods for preparing the nanowires, and methods of using the nanowires in metal catalyzed oxidation of small organic molecules.

19. 发明申请

US20210214851A1 METAL OXIDE NANOWIRES IN SUPPORTED NANOPARTICLE CATALYSIS 有权
公开(公告)号：US20210214851A1
公开(公告)日：2021-07-15
申请号：US16739498
申请日：2020-01-10
申请人： Fordham University
发明人： Christopher Koenigsmann , Alexander Charles Santulli
IPC分类号： C25B11/04 , C25B1/00
摘要： The present disclosure is concerned with metal oxide nanowires, and more specifically, to crystalline ruthenium oxide (RuO2) nanowires, sol-gel synthetic methods for preparing the nanowires, and methods of using the nanowires in metal catalyzed oxidation of small organic molecules.

20. 发明授权

EP0859631B9 TREATMENT OR PREVENTION OF NEOPLASTIC AND INFECTIOUS DISEASES WITH HEAT SHOCK/STRESS PROTEINS 失效
标题翻译：治疗和传染病预防与热休克/应激蛋白肿瘤
公开(公告)号：EP0859631B9
公开(公告)日：2010-07-28
申请号：EP96931527.4
申请日：1996-09-11
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K.
IPC分类号： A61K39/385 , A61K39/12 , A61K39/02 , A61K39/00 , A61K35/12 , G01N33/53 , G01N33/555 , G01N33/567
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/52 , A61K2039/525 , A61K2039/6043 , A61K2039/622 , G01N33/56977 , G01N33/574 , Y02A50/403 , Y02A50/41 , Y02A50/466 , Y02A50/478 , Y10S435/81
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式